BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 26724189)

  • 1. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
    Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
    J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
    Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
    Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
    Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
    Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
    Kollárová-Brázdová P; Lenčová-Popelová O; Karabanovich G; Kocúrová-Lengvarská J; Kubeš J; Váňová N; Mazurová Y; Adamcová M; Jirkovská A; Holečková M; Šimůnek T; Štěrbová-Kovaříková P; Roh J; Štěrba M
    Clin Sci (Lond); 2021 Aug; 135(15):1897-1914. PubMed ID: 34318878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
    Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
    J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
    Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
    Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
    Simůnek T; Klimtová I; Kaplanová J; Mazurová Y; Adamcová M; Sterba M; Hrdina R; Gersl V
    Eur J Heart Fail; 2004 Jun; 6(4):377-87. PubMed ID: 15182761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up.
    Pokorná Z; Kollárová-Brázdová P; Lenčová-Popelová O; Jirkovský E; Kubeš J; Mazurová Y; Adamcová M; Holečková M; Palička V; Šimůnek T; Štěrba M
    Clin Sci (Lond); 2022 Jan; 136(1):139-161. PubMed ID: 34878093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
    Popelová O; Sterba M; Hasková P; Simůnek T; Hroch M; Guncová I; Nachtigal P; Adamcová M; Gersl V; Mazurová Y
    Br J Cancer; 2009 Sep; 101(5):792-802. PubMed ID: 19623174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
    Bavlovič Piskáčková H; Jansová H; Kubeš J; Karabanovich G; Váňová N; Kollárová-Brázdová P; Melnikova I; Jirkovská A; Lenčová-Popelová O; Chládek J; Roh J; Šimůnek T; Štěrba M; Štěrbová-Kovaříková P
    Sci Rep; 2021 Feb; 11(1):4456. PubMed ID: 33627707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.
    Bures J; Jirkovska A; Sestak V; Jansova H; Karabanovich G; Roh J; Sterba M; Simunek T; Kovarikova P
    Toxicology; 2017 Dec; 392():1-10. PubMed ID: 28941780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage.
    Keresteš V; Kubeš J; Applová L; Kollárová P; Lenčová-Popelová O; Melnikova I; Karabanovich G; Khazeem MM; Bavlovič-Piskáčková H; Štěrbová-Kovaříková P; Austin CA; Roh J; Štěrba M; Šimůnek T; Jirkovská A
    Toxicol Sci; 2024 Mar; 198(2):288-302. PubMed ID: 38290791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
    Hasinoff BB; Patel D; Wu X
    Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity.
    Sterba M; Popelová O; Simunek T; Mazurová Y; Potácová A; Adamcová M; Kaiserová H; Ponka P; Gersl V
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1336-47. PubMed ID: 17003229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart.
    Jirkovský E; Jirkovská A; Bureš J; Chládek J; Lenčová O; Stariat J; Pokorná Z; Karabanovich G; Roh J; Brázdová P; Šimůnek T; Kovaříková P; Štěrba M
    J Pharmacol Exp Ther; 2018 Mar; 364(3):433-446. PubMed ID: 29273587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH).
    Sterba M; Popelová O; Simůnek T; Mazurová Y; Potácová A; Adamcová M; Guncová I; Kaiserová H; Palicka V; Ponka P; Gersl V
    Toxicology; 2007 Jun; 235(3):150-66. PubMed ID: 17459556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.
    Hasinoff BB; Patel D; Wu X
    Cardiovasc Toxicol; 2020 Jun; 20(3):312-320. PubMed ID: 31773441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
    Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
    PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits.
    Simůnek T; Sterba M; Holecková M; Kaplanová J; Klimtová I; Adamcová M; Gersl V; Hrdina R
    Biometals; 2005 Apr; 18(2):163-9. PubMed ID: 15954742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy.
    Szponar J; Ciechanski E; Ostrowska-Lesko M; Gorska A; Tchorz M; Dabrowska A; Dudka J; Murias M; Kowalczyk M; Korga-Plewko A; Mandziuk S
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.